Clinical trials: Aggression
Agitation, Alzheimer's Disease
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Participants With Alzheimer's Disease
The objectives of the study are to evaluate the safety, tolerability and efficacy of AVP-923 compared to placebo, for the treatment of symptoms of agitation in participants with Alzheimer's Disease (AD).
- Trial name
- NCT01584440
- Testing
- AVP-923-20, AVP-923-30
- Where
- 44 sites in United States
- Volunteers
- 220 people
- Sponsor
- Avanir Pharmaceuticals
Aggressive Systemic Mastocytosis, Systemic Mastocytosis-associated Hematologic Non-mast Cell Disease
(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies
This is a Phase 1, open-label, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antineoplastic activity of avapritinib (also known as BLU-285), administered…
- Conditions
- Aggressive Systemic Mastocytosis, Systemic Mastocytosis-associated Hematologic Non-mast Cell Disease, Mast Cell Leukemia, Relapsed or Refractory Myeloid Malignancies
- Trial name
- NCT02561988
- Testing
- Avapritinib
- Where
- 11 sites in United States, United Kingdom
- Volunteers
- 86 people
- Sponsor
- Blueprint Medicines Corporation
Non-Hodgkin Lymphoma
A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
This study will assess the efficacy and safety of mosunetuzumab in combination with polatuzumab vedotin (M+P) in participants with relapsed or refractory (R/R) diffuse-large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma…
- Trial name
- SUNMO (NCT05171647)
- Testing
- Mosunetuzumab, Polatuzumab vedotin, Tocilizumab
- Where
- 51 sites in United States, Argentina and 11 more
- Volunteers
- 208 people
- Sponsor
- Hoffmann-La Roche
B-Cell Non Hodgkin Lymphoma
Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL
This is a phase 2/3 open label, multicenter trial testing blinatumomab monotherapy for the treatment of subjects with Relapsed/Refractory (R/R) aggressive B-NHL not achieving CMR after 2 cycles of standard platinum-based…
- Trial name
- NCT02910063
- Testing
- Blinatumomab
- Where
- 31 sites in United States, Australia and 6 more
- Volunteers
- 41 people
- Sponsor
- Amgen
Prostate Cancer
Evaluation of a Blood Biomarker to Try and Distinguish Between the Presence or Absence of Aggressive Prostate Cancer
A Laboratory Study to Evaluate Urine and Blood Biomarkers That Can Distinguish Between the Presence or Absence of Aggressive Prostate Cancer
- Trial name
- NCT03256630
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- Genomic Health®, Inc.
Post-transplant Hepatitis C
Expanded Access Program of Sofosbuvir With Ribavirin and With or Without Pegylated Interferon in Aggressive Post-transplant Hepatitis C
This is a single arm, open-label study which will be opened at specific clinical sites at the request of an investigator for the treatment of individual subjects for whom there are no other treatment options.
- Trial name
- NCT01779518
- Testing
- Sofosbuvir, Ribavirin, Pegylated Interferon
- Sponsor
- Gilead Sciences
Schizophrenia, Schizoaffective Disorder
Study on the Safety and Effectiveness of Risperidone Treatment of Acute Psychotic Patients
The purpose of this study was to evaluate the safety of risperidone treatment in acute psychotic patients that require an admission into emergency department.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders
- Trial name
- NCT00515489
- Testing
- Risperidone
- Volunteers
- 1,882 people
- Sponsor
- Janssen-Cilag, S.A.
Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma
MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine
This is a single-arm, open-label, multicenter, dose escalation, phase 1-2 study of alisertib (MLN8237) administered in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)/transformed follicular lymphoma…
- Conditions
- Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma, Mantle Cell Lymphoma, Burkitt's Lymphoma
- Trial name
- NCT01397825
- Testing
- Alisertib (MLN8237), Rituximab, Vincristine
- Where
- 25 sites in United States, Italy and 2 more
- Volunteers
- 45 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Psychomotor Agitation, Acute Disease
IMPACT: A Study to Explore the Efficacy and Safety of Paliperidone ER in Patients With Acute Agitation
This study will investigate the effect of paliperidone ER (in combination with or without benzodiazepines) in patients presenting with symptoms of agitation and/or aggression in the context of psychosis, and will generate data…
- Trial name
- NCT01050478
- Testing
- Paliperidone ER, Benzodiazepine
- Where
- 14 sites in Belgium
- Volunteers
- 56 people
- Sponsor
- Janssen Cilag N.V./S.A.
Agitation and Aggression in Alzheimer's Disease
A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
To evaluate the safety and tolerability of pimavanserin over 52 weeks of treatment in subjects with probable AD who have symptoms of agitation and aggression
- Trial name
- NCT03118947
- Testing
- Pimavanserin
- Where
- 28 sites in United States, Chile and 3 more
- Volunteers
- 79 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Advanced Systemic Mastocytosis, Aggressive Systemic Mastocytosis
(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
This is an open-label, single arm, Phase 2 study evaluating the efficacy and safety of avapritinib (BLU-285) in patients with advanced systemic mastocytosis (AdvSM), including patients with aggressive SM (ASM), SM with associated…
- Conditions
- Advanced Systemic Mastocytosis, Aggressive Systemic Mastocytosis, Systemic Mastocytosis With an Associated Hematologic Neoplasm, Mast Cell Leukemia
- Trial name
- NCT03580655
- Testing
- Avapritinib
- Where
- 32 sites in United States, Austria and 10 more
- Volunteers
- 107 people
- Sponsor
- Blueprint Medicines Corporation
DLBCL, High-grade B-cell Lymphoma (HGBCL)
First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
The purpose of this trial is to measure the following in participants with relapsed and/or refractory B-cell lymphoma who receive epcoritamab, an antibody also known as EPKINLY™ and GEN3013 (DuoBody®-CD3xCD20): The dose schedule…
- Conditions
- DLBCL, High-grade B-cell Lymphoma (HGBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), FL
- Trial name
- EPCORE™ NHL-1 (NCT03625037)
- Testing
- Epcoritamab
- Where
- 85 sites in United States, Australia and 13 more
- Volunteers
- 666 people
- Sponsor
- Genmab
Symptomatic, Aggressive, Sporadic, Unresectable, Locally, Advanced/Metastatic Medullary Thyroid Cancer (MTC)
Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer
This is a European multinational, multicenter, non-interventional (observational) and prospective study. It is carried on to confirm in real life conditions the benefit/risk of vandetanib (CAPRELSA™) 300 mg, both in RET negative…
- Trial name
- Caprelsa104 (NCT01945762)
- Testing
- Vandetanib 300 mg
- Where
- 8 sites in Belgium, France and 6 more
- Volunteers
- 31 people
- Sponsor
- Genzyme, a Sanofi Company